SCHEMBL8224022

SCHEMBL8224022

C[C@H](O)[C@H](NC(=O)OC(C)(C)C)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.56
CTSL P07711 4/20 0.56
SYK P43405 1/20 0.55
PPARA Q07869 3/20 0.52
KLK5 Q9Y337 2/20 0.51
APP P05067 1/20 0.51
ATM Q13315 1/20 0.49
MAPT P10636 1/20 0.48
POLB P06746 1/20 0.47
CTSB P07858 2/20 0.47
CTSK P43235 2/20 0.47
PPARG P37231 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133276 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL31220447 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL20993818 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL6181712 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL13827783 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL3133278 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
SCHEMBL16488769 1.00 CTSS (0.56) CTSSCTSLSYKPPARAKLK5
Hydrochloric Acid SCHEMBL28347449 0.99 CTSS (0.55) CTSSCTSLSYKPPARAKLK5
SCHEMBL12873000 0.91 KLK5 (0.57) CTSSCTSLSYKPPARAKLK5
SCHEMBL6388701 0.91 KLK5 (0.57) CTSSCTSLSYKPPARAKLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235719-A1 DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2025-11-13 WO disclosed
CN-111148739-B Cyclic peptide antibiotics 豪夫迈·罗氏有限公司 2025-06-03 CN disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 US disclosed
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
EP-2007794-B1 LYSOBACTIN AMIDES AICURIS GMBH & CO KG (DE) 2011-09-14 EP disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed
US-20090163696-A1 METHOD FOR PREPARING LYSOBACTIN DERIVATIVES BAYER HEALTHCARE AG (DE) 2009-06-25 US disclosed
US-20090163696-A1 METHOD FOR PREPARING LYSOBACTIN DERIVATIVES BAYER HEALTHCARE AG (DE) 2009-06-25 US disclosed
WO-2007118693-A1 PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES AICURIS GMBH & CO. KG (DE) 2007-10-25 WO disclosed
WO-2007118691-A1 LYSOBACTIN AMIDES AICURIS GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 CTSS 1755/4885CTSL 850/4885SYK 545/4885
US-20090163696-A1 METHOD FOR PREPARING LYSOBACTIN DERIVATIVES DLST, VIP, HAMP CTSS 642/4885CTSL 142/4885SYK 2866/4885
US-20090203582-A1 LYSOBACTIN AMIDES AADAT, HAMP, DLST CTSS 660/4885CTSL 196/4885SYK 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.